Stockscreener 앱 받기
1.68
1.20%
0.02
시간 외 거래:
1.68
Fate Therapeutics Inc 주식(FATE)의 최신 뉴스
Critical Survey: Fate Therapeutics (NASDAQ:FATE) versus HilleVax (NASDAQ:HLVX) - Defense World
Fmr LLC Buys 46,892 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Sees Significant Growth in Short Interest - MarketBeat
FATE LAWSUIT ALERT: Levi & Korsinsky Notifies Fate Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Marketscreener.com
Fate Therapeutics' SWOT analysis: cell therapy stock shows promise amid risks - Investing.com
Fate Therapeutics' SWOT analysis: cell therapy stock shows promise amid risks By Investing.com - Investing.com South Africa
BNP Paribas Financial Markets Raises Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
FATE stock touches 52-week low at $1.96 amid market challenges - Investing.com
FATE stock touches 52-week low at $1.96 amid market challenges By Investing.com - Investing.com South Africa
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus - The Manila Times
Fate Therapeutics Presents New Phase 1 Clinical Data of - GlobeNewswire
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for - EIN News
Fate Therapeutics' Off-the-Shelf CAR T Shows Breakthrough Results in Lupus TreatmentPhase 1 Data - StockTitan
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics makes Bob Valamehr president and CEO - MSN
Brokerages Set Fate Therapeutics, Inc. (NASDAQ:FATE) PT at $6.75 - MarketBeat
Bob Valamehr to succeed CEO Scott Wolchko at Fate - BioCentury
Fate Therapeutics appoints new CEO as Wolchko retires By Investing.com - Investing.com Australia
Fate Therapeutics Announces Leadership Transition for 2025 - TipRanks
Fate Therapeutics Taps Bob Valamehr to Be CEO - MarketWatch
Fate Therapeutics Announces Leadership Transition - The Manila Times
Fate Therapeutics appoints new CEO as Wolchko retires - Investing.com
Fate Therapeutics, Inc. Announces President Changes - Marketscreener.com
Vestal Point Capital LP Sells 315,000 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Sees Large Drop in Short Interest - MarketBeat
Fate Therapeutics to Present at Upcoming December Investor Conferences - The Manila Times
Fate Therapeutics (NASDAQ:FATE) Given Hold Rating at Needham & Company LLC - Defense World
Fate Therapeutics' SWOT analysis: clinical progress boosts stock outlook - Investing.com
Fate Therapeutics' SWOT analysis: clinical progress boosts stock outlook By Investing.com - Investing.com Canada
FATE Presents Encourgaing Data From Lupus Study, Stock Gains - MSN
Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options - Seeking Alpha
Fate stock closes 12% higher after soaring 73% on drug data (update) - MSN
Bank of America Upgrades Fate Therapeutics (NASDAQ:FATE) to Neutral - Defense World
Needham & Company LLC Reaffirms "Hold" Rating for Fate Therapeutics (NASDAQ:FATE) - MarketBeat
Fate Thera rockets on early data for FT819 - The Pharma Letter
Analyst cites quality-of-life improvements while maintaining Hold on Fate Therapeutics stock - Investing.com
BofA upgrades Fate Therapeutics to neutral; target to $3 from $3.50 By Investing.com - Investing.com UK
Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence - The Manila Times
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence - GlobeNewswire
Fate Therapeutics (FATE) Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study - StreetInsider.com
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed - GlobeNewswire
Wedbush Decreases Earnings Estimates for Fate Therapeutics - MarketBeat
Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Fate Therapeutics stock hits 52-week low at $2.09 By Investing.com - Investing.com Canada
2.88%
2.65%
자본화:
|
볼륨(24시간):